文献速递流行病学与生物统计临床试验与 GCP

SSRIs与SNRIs治疗焦虑、强迫及相关应激障碍的三层次网络荟萃分析

Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
PubMed 文献 · PLoS Med · 2021-06-10

该三层次网络荟萃分析纳入135项随机对照试验(n=30,245),比较SSRIs、SNRIs与安慰剂在焦虑、强迫及相关应激障碍多个症状域中的疗效与可接受性。结果显示所有药物对内化症状的聚合指标均优于安慰剂(SMD -0.56,95%CI -0.62至-0.51,p<0.001),且在各症状域和诊断类别中一致;药物间疗效与可接受性差异微小。

要点

  • SSRIs和SNRIs对焦虑、强迫及相关应激障碍的内化症状均优于安慰剂。
  • 药物间疗效和可接受性差异很小,选择可侧重耐受性与个体化。
  • 三层次网络荟萃分析整合多评估工具数据,减少信息排除偏倚。

核心结论

  • 所有SSRIs和SNRIs对多个症状域及所有纳入诊断类别的患者均有效。
  • 药物间在疗效和可接受性方面差异极小。

研究设计与样本

  • 三层次网络荟萃分析,检索MEDLINE、PsycINFO、Embase和Cochrane Library(至2015年4月23日,更新至2020年11月11日)。
  • 纳入135项随机对照试验,共30,245名参与者(成人和儿童)。
  • 主要结局为这些障碍内化症状的聚合测量,次要结局包括特定症状域和治疗中断率。

主要发现

  • 所有药物对内化症状聚合指标均优于安慰剂(SMD -0.56,95%CI -0.62至-0.51,p<0.001)。
  • 所有症状域和所有诊断类别中均显示显著效果。
  • 限制为各诊断最常用评估工具时结果仍显著,但排除了72.71%的结局测量。
  • 药物间成对比较显示疗效和可接受性差异仅很小。

临床怎么用

  • SSRIs和SNRIs均可用于焦虑、强迫及相关应激障碍的多个症状域治疗。
  • 药物选择可综合考虑疗效、可接受性及患者个体情况,因药物间差异微小。

局限性

  • 多数结局存在中等异质性。
  • 多数试验存在中等偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anxiety, obsessive-compulsive, and stress-related disorders frequently co-occur, and patients often present symptoms of several domains. Treatment involves the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), but data on comparative efficacy and acceptability are lacking. We aimed to compare the efficacy of SSRIs, SNRIs, and placebo in multiple symptom domains in patients with these diagnoses over the lifespan through a 3-level network meta-analysis. METHODS AND FINDINGS: We searched for published and unpublished randomized controlled trials that aimed to assess the efficacy of SSRIs or SNRIs in participants (adults and children) with diagnosis of any anxiety, obsessive-compulsive, or stress-related disorder in MEDLINE, PsycINFO, Embase, and Cochrane Library from inception to 23 April 2015, with an update on 11 November 2020. We supplemented electronic database searches with manual searches for published and unpublished randomized controlled trials registered in publicly accessible clinical trial registries and pharmaceutical companies' databases. No restriction was made regarding comorbidities with any other mental disorder, participants' age and sex, blinding of participants and researchers, date of publication, or study language. The primary outcome was the aggregate measure of internalizing symptoms of these disorders. Secondary outcomes included specific symptom domains and treatment discontinuation rate. We estimated standardized mean differences (SMDs) with 3-level network meta-analysis with random slopes by study for medication and assessment instrument. Risk of bias appraisal was performed using the Cochrane Collaboration's risk of bias tool. This study was registered in PROSPERO (CRD42017069090). We analyzed 469 outcome measures from 135 studies (n = 30,245). All medications were more effective than placebo for the aggregate measure of internalizing symptoms (SMD -0.56, 95% CI -0.62 to -0.51, p < 0.001), for all symptom domains, and in patients from all diagnostic categories. We also found significant results when restricting to the most used assessment instrument for each diagnosis; nevertheless, this restriction led to exclusion of 72.71% of outcome measures. Pairwise comparisons revealed only small differences between medications in efficacy and acceptability. Limitations include the moderate heterogeneity found in most outcomes and the moderate risk of bias identified in most of the trials. CONCLUSIONS: In this study, we observed that all SSRIs and SNRIs were effective for multiple symptom domains, and in patients from all included diagnostic categories. We found minimal differences between medications concerning efficacy and acceptability. This three-level network meta-analysis contributes to an ongoing discussion about the true benefit of antidepressants with robust evidence, considering the significantly larger quantity of data and higher statistical power when compared to previous studies. The 3-level approach allowed us to properly assess the efficacy of these medications on internalizing psychopathology, avoiding potential biases related to the exclusion of information due to distinct assessment instruments, and to explore the multilevel structure of transdiagnostic efficacy.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Gosmann NP, Costa MA, Jaeger MB, et al. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. PLoS Med. 2021. PMID: 34111122. doi:10.1371/journal.pmed.1003664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。